Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received an average recommendation of “Moderate Buy” from the eleven analysts that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $29.2857.

ZVRA has been the subject of a number of research analyst reports. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research note on Tuesday, June 9th. HC Wainwright restated a “buy” rating and set a $26.00 price objective on shares of Zevra Therapeutics in a research note on Tuesday, June 23rd. Citizens Jmp increased their price objective on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “market outperform” rating in a report on Tuesday, June 9th. Guggenheim increased their price objective on Zevra Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Finally, Maxim Group increased their price objective on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, June 10th.

Institutional Investors Weigh In On Zevra Therapeutics

Large investors have recently made changes to their positions in the stock. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in shares of Zevra Therapeutics in the 4th quarter valued at approximately $53,000. Russell Investments Group Ltd. lifted its stake in Zevra Therapeutics by 235.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after purchasing an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares during the period. Creative Planning bought a new position in Zevra Therapeutics during the second quarter worth about $92,000. Finally, Quarry LP bought a new position in Zevra Therapeutics during the third quarter worth about $103,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Trading Up 3.6%

Zevra Therapeutics stock opened at $14.01 on Tuesday. The firm has a market capitalization of $828.20 million, a P/E ratio of 7.04 and a beta of 0.91. Zevra Therapeutics has a 1 year low of $7.16 and a 1 year high of $14.27. The business has a 50-day moving average of $11.41 and a 200-day moving average of $9.85.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.12. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The company had revenue of $36.22 million during the quarter, compared to analyst estimates of $31.96 million. Research analysts anticipate that Zevra Therapeutics will post 0.56 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.